Purchase this article with an account.
Hugo E. Sepulveda-Vazquez, Jose Luis Guerrero-Naranjo, Fernando Schoonewolff, Hugo Quiroz-Mercado, Hampar L. Karageozian, John Y. Park, Vicken Karageozian, Sonia Corredor, Abelardo Rodriguez-Reyes, Marc Kirshbaum; Intravitreal Injection of Integrin Peptide ALG-1001 for the Induction of Posterior Vitreous Detachment in Rabbit Eyes. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5360.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and assess the effect of intravitreal injections of ALG-1001 on the vitreoretinal junction for a facilitating effect on posterior vitreous detachment (PVD) in rabbit eyes.
Prospective, preclinical trial. A first group of five New Zealand white rabbits received 100 µL intravitreal injections of 2.5 mg of ALG-1001 Integrin Peptide in their right eyes. A second group of four New Zealand white rabbits receive 100 µL intravitreal injections of 2.5 mg of ALG-1001 Integrin Peptide plus 0.02% Disodium EDTA solution in their right eyes. A third group of four New Zealand white rabbits received 100 µL intravitreal injections of balanced salt solution (BSS) in their right eyes (control group). No rabbit received intravitreal injections in their left eye. Slit lamp examination, dilated fundus exam, electroretinogram (ERG) and ultrasonography (USG) were performed before and one day after the injections in all eyes. Adverse events were evaluated. Vitrectomy was performed in all eyes one day after the injection to evaluate the presence of posterior vitreous detachment and vitreous liquefaction in all treated eyes. All rabbits were euthanized after vitrectomy, eyes enucleated and light and scanning electron microscopy performed.
In the first group PVD occurred in all eyes injected (100%), 3 of them were PVD grade 3, one grade 2 and one grade 1; vitreous liquefaction was found during vitrectomy in 4 of 5 eyes (80%). In the second group with combined drugs we found PVD in four injected eyes (100%), 2 eyes with grade 3 PVD and 2 eyes with grade 1; vitreous liquefaction was found in 2 out of 4 eyes (50%). In the third group injected with BSS we found PVD in only 2 eyes (50%), 1 eye with stage 2 PVD and one with stage 1, 2 eyes presented no PVD. We observed vitreous liquefaction in only 1 of 4 eyes in this control group (25%). PVD was not observed during the USG in the left eye of any rabbit.
Intravitreal injection of ALG-1001 integrin peptide seems to be a safe procedure for producing total PVD’s, with no adverse effects. Integrin peptides could be useful as an adjunct for vitrectomy. Studies with larger sample sizes are needed to confirm these findings.
This PDF is available to Subscribers Only